Physician profile
Brian Shayota
NPI 1861806523
$92,910.52
in general payments reported to CMS, 2019-2025
12 companies · $59K in 2025
The $59K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $120 · 2021: $30.00 · 2022: $9,773 · 2023: $7,735 · 2024: $16K · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Honoraria: $17K · Travel and Lodging: $15K · Consulting Fee: $14K · Food and Beverage: $2,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,233.54 |
| Honoraria | $17,307.00 |
| Travel and Lodging | $14,934.80 |
| Consulting Fee | $14,228.50 |
| Food and Beverage | $2,128.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $32,599.66 | 2024-2025 | Elfabrio, Lamzede |
| Genzyme Corporation | $28,353.11 | 2023-2025 | |
| Horizon Therapeutics Plc | $15,675.10 | 2022-2023 | Ravicti |
| Amicus Therapeutics, INC. | $7,967.13 | 2024-2025 | Opfolda, Pombiliti |
| Travere Therapeutics, INC. | $4,227.31 | 2022-2025 | |
| Modernatx, INC. | $3,377.18 | 2024 | |
| Biomarin Pharmaceutical INC. | $249.35 | 2022-2025 | Palynziq |
| Shire North American Group INC | $156.00 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $150.00 | 2020-2021 | |
| Intrabio INC | $106.10 | 2025 | Aqneursa |
| Amgen INC. | $28.27 | 2024 | Ravicti |
| Takeda Pharmaceuticals U.S.A., INC. | $21.31 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Shayota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.